Highlights Marinus Pharmaceuticals, Inc.

Equities

MRNS

US56854Q2003

Real-time Estimate Cboe BZX Other stock markets 12:33:00 2024-05-08 pm EDT			5-day change	1st Jan Change
1.545 ^USD	-1.59%		+5.95%	-85.67%

02:57pm	Earnings Flash (MRNS) MARINUS PHARMACEUTICALS Reports Q1 Revenue $7.7M, vs. Street Est of $9.1M	MT
01:00pm	Marinus Pharmaceuticals, Inc. Increases Earnings Guidance for Full Year 2024	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Earnings Flash (MRNS) MARINUS PHARMACEUTICALS Reports Q1 Revenue $7.7M, vs. Street Est of $9.1M	08:57am	MT
Marinus Pharmaceuticals, Inc. Increases Earnings Guidance for Full Year 2024	07:00am	CI
Sector Update: Health Care Stocks Softer Late Afternoon	Apr. 15	MT
Marinus Pharmaceuticals, Inc. Provides Update on the Phase 3 RAISE Trial	Apr. 15	CI
Marinus Pharmaceuticals Q4 Net Loss Wider Than Expected While Revenue Misses Forecast; Shares Drop Premarket	Mar. 06	MT
Marinus Pharmaceuticals Q4 Net Loss Narrows, Revenue Higher; Shares Plunge After-Hours	Mar. 05	MT
Marinus Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 05	CI
Earnings Flash (MRNS) MARINUS PHARMACEUTICALS Posts Q4 Revenue $7.2M, vs. Street Est of $8.1M	Mar. 05	MT
Marinus Pharmaceuticals, Inc. Provides Earnings Guidance for 2024	Mar. 05	CI
Marinus Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 05	CI
Marinus Pharmaceuticals Raises 2023 Product Revenue Expectation	Jan. 04	MT
Marinus Pharmaceuticals, Inc. Announces Seven Presentations at AES 2023, New Publication in Epilepsia and Results from the Second Generation Formulation MAD Study	Nov. 20	CI
Earnings Flash (MRNS) MARINUS PHARMACEUTICALS Posts Q3 Revenue $7.3M, vs. Street Est of $6.3M	Nov. 07	MT
Marinus Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI
Marinus Pharmaceuticals, Inc. Updates Revenue Guidance for the Fiscal Year 2023	Nov. 07	CI
Marinus Pharmaceuticals, Inc. Initiates Global Access Program for ZTALMY(R) Oral Suspension CV	Nov. 07	CI
Marinus Pharmaceuticals, Inc. Provides Revenue Guidance for 2023	23-08-10	CI
Earnings Flash (MRNS) MARINUS PHARMACEUTICALS Reports Q2 Revenue $6.1M, vs. Street Est of $5.7M	23-08-10	MT
Marinus Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Marinus Pharmaceuticals Says European Commission Approves Ztalmy Oral Suspension	23-07-31	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Marinus Pharmaceuticals, Inc.

Equities

MRNS

US56854Q2003

Highlights

Filters